NCT06476132View on ClinicalTrials.gov

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

PHASE2RecruitingINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

June 30, 2027

Conditions
Lung Transplant
Interventions
DRUG

Belumosudil

Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.

DRUG

Placebo for Belumosudil

Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.

Trial Locations (8)

10016

RECRUITING

NYU Langone Health (Site #: 71177), New York

19104

RECRUITING

University of Pennsylvania (Site #: 71111), Philadelphia

21287

RECRUITING

Johns Hopkins (Site #: 71119), Baltimore

27710

RECRUITING

Duke University (Site #: 71139), Durham

44195

RECRUITING

Cleveland Clinic (Site #: 71101), Cleveland

45229

RECRUITING

Cincinnati Children's Hospital Medical Center (Site #: 71017), Cincinnati

63130

RECRUITING

Washington University (Site #: 71157), St Louis

90095

RECRUITING

University of California, Los Angeles (Site #: 71123), Los Angeles

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH